According to marketinforesearch.com’s new report "Opportunity Analyzer: Opioid-Induced Constipation - Opportunity Analysis and Forecasts to 2017", 2012 sales for opioid-induced constipation (OIC) to be approximately $144.42m across the six major pharmaceutical markets covered in this forecast. By 2017, OIC sales will grow to approximately $1.98 billion, at a CAGR of 31.9%. The majority of sales will come from the US, which will represent more than 90% of the market (based on 6MM) in 2017.
A common strategy being undertaken by companies in the OIC space is to enter partnerships and acquisitions in a bid for companies to broaden their pipeline portfolio. Examples include the acquisitions of Adolor Corporation by Cubist Pharmaceuticals and the licensing of naloxegol to AstraZeneca by Nektar.
With the vast majority of novel therapeutic agents for OIC being developed by small to medium-sized pharmaceutical and biotechnology companies, GlobalData anticipates that licensing activity and the formation of new partnerships with companies possessing strong GI sales experience will be key in competing in a soon-to-be-congested market populated by many me-too drugs.
Besides the advent of efficacious drugs, improving diagnosis and increasing the awareness of new treatments is a key unmet need essential in increasing the drug-treatment rate for OIC. The current OIC therapeutic market is dominated by inexpensive, widely available laxatives. Despite a lack of strong evidence and poor clinical efficacy, they are currently broadly accepted as the mainstay of constipation relief. The success of prescription OIC therapies compared with that of OTC laxatives will depend on extensive marketing. Such marketing must serve to increase both patient and physician awareness of the non-laxative prescription options when treating constipation, in particular for OIC.
Read more details at http://marketinforesearch.com/gastrointestinal-c-5_469/opportunityanalyzer-opioidinduced-constipation-opportunity-analysis-and-forecasts-to-2017-p-23258.html
About Report:
- Overview of OIC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines
- Annualized OIC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast to 2017
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs
- Analysis of the current and future market competition in the global OIC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
No comments:
Post a Comment